Skip to main content
. 2017 Jun 6;2017(6):CD012143. doi: 10.1002/14651858.CD012143.pub2

Analysis 1.10.

Analysis 1.10

Comparison 1 DAA on or on the way to the market versus placebo/no intervention, Outcome 10 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to specific ethnicities.